2. Academic Validation
  3. Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes

Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes

  • ACS Nano. 2025 Feb 4;19(4):4195-4212. doi: 10.1021/acsnano.4c08767.
Yichao Lu 1 2 3 4,  Xinyu Shan 1,  Jiaxin Huang 1,  Huanli Zhou 1,  Ying Zhu 1,  Sijie Wang 1,  Zhenyu Luo 1,  Xu Liu 1,  Xuemeng Guo 1,  Yingying Shi 1,  Yilong Hu 1,  Huihui Liu 1,  Junlei Zhang 1,  Ping Huang 2 3 4,  Lihua Luo 1 5,  Jian You 1 5 6
Affiliations

Affiliations

  • 1 College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
  • 2 Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.
  • 3 Zhejiang Provincial Clinical Research Center for Head & Neck Cancer, Hangzhou 310014, China.
  • 4 Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou 310014, China.
  • 5 Zhejiang-California International NanoSystems Institute, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
  • 6 Jinhua Institute of Zhejiang University, 498 Yiwu Street, Jinhua, Zhejiang 321299, P. R. China.
PMID: 39846120 DOI: 10.1021/acsnano.4c08767
Abstract

Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive Reactive Oxygen Species (ROS). Therefore, to address these issues, in this study, we targeted the upstream pathogenesis by designing a pro-Th1 Adjuvant nanoemulsion loaded with poly(I:C) and encapsulated with the ROS-scavenger vitamin E, termed PV-NE. PV-NE effectively rebalanced the Th1/Th2 immune response and reduced ROS levels both in vivo and ex vivo, leading to the restoration of immune balance in AD-affected skin and alleviation of symptoms such as lichenification and erythematous patches. In conclusion, our development of the reductive Adjuvant nanosystem PV-NE demonstrates its biocompatibility and efficacy in combating AD progression without the use of immunosuppressant glucocorticoids. This has the potential to significantly impact the design and enhancement of pharmacotherapy in future clinical research aimed at curing AD.

Keywords

antitype 2 autoimmune inflammation; atopic dermatitis; dendritic cells function modulation; immune balance restoration; oxidative stress.

Figures
Products